麻杏甘石汤治疗儿童社区获得性肺炎的随机双盲安慰剂对照多中心试验
该随机双盲安慰剂对照多中心试验纳入71例3-6岁社区获得性肺炎患儿,评估麻杏甘石汤的疗效与安全性。结果显示麻杏甘石汤组恢复及显效率显著提高,症状评分显著降低,退热时间缩短,且两组均未观察到副作用。
要点
- 麻杏甘石汤可提高儿童CAP的恢复及显效率。
- 麻杏甘石汤可降低症状评分并缩短退热时间。
- 研究期间两组均未观察到副作用。
核心结论
- 麻杏甘石汤能有效改善儿童社区获得性肺炎的疾病疗效和临床症状,并缩短退热时间,可能作为替代疗法。
研究设计与样本
- 在天津3个研究中心开展的随机、双盲、安慰剂对照、多中心试验,纳入71例(麻杏甘石汤组36例,安慰剂组35例)3-6岁、发病48小时内的社区获得性肺炎患儿。
主要发现
- 干预10天后,麻杏甘石汤组恢复和显著有效的患者比例较对照组显著增加(34.85% [95% CI, 12.44%-57.26%];p < 0.05)。
- 麻杏甘石汤组症状评分显著降低(p < 0.001)。
- 麻杏甘石汤组估计退热时间较对照组缩短(p < 0.05)。
- 整个研究期间,麻杏甘石汤组和对照组均未观察到副作用。
临床怎么用
- 对于3-6岁、发病48小时内的社区获得性肺炎患儿,可考虑使用麻杏甘石汤作为替代疗法以改善疗效和症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: As one of the most commonly used Chinese medicine formula in the manage of respiratory diseases, Maxing Ganshi Decoction (MGD) has been demonstrated to improve the clinical symptoms of pneumonia. To evaluate the efficacy and safety of MGD in treating children with community-acquired pneumonia (CAP), we conducted the clinical trial. Methods: A randomized, double-blind, placebo-controlled, multicenter trial was conducted in 3 study sites in Tianjin, China. MDG or placebo were randomly given to patients aged 3-6 years with onset of CAP within 48 h. Changes in disease efficacy during the study period (which was measured as recovery, significant effect, improvement and no effect) was evaluated as the primary outcome. Time from enrollment to fever resolution was assessed as the secondary outcome. The adverse event was analyzed as safety evaluation. Results: A total of 71 patients (36 in MGD and 35 in placebo) were randomized and completed the whole study. The patient demographics and other characteristics at baseline were similar between the 2 groups (p > 0.05). After 10 days of intervention, the proportion of recovered and significant effective patients was increased significantly in the MGD group (34.85% [95% CI, 12.44%-57.26%]; p < 0.05) compared with the control group. Besides, the symptom score of the MGD group was lowered significantly (p < 0.001). The estimated time to fever resolution in the MGD group was also reduced compared with the control group (p < 0.05). During the whole study, no side effects were observed in both MGD and control groups. Conclusion: MGD was effective in improving disease efficacy, clinical symptoms and reducing time to fever resolution in patients with childhood CAP, which suggested that MGD may be used as an alternative therapy in the treatment of childhood CAP. Clinical Trial Registration: http://www.chictr.org.cn/showproj.aspx?proj=5612, identifier 13003955.
引用
- Zheng Y, Shi C, Han Y, et al. Efficacy and safety of a Chinese herbal formula Maxing Ganshi Decoction in children with community-acquired pneumonia: A randomized, double-blind, placebo-controlled, multicenter trial. Front Pharmacol. 2022. PMID: 36120338. doi:10.3389/fphar.2022.948831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。